Posted by Michael Wonder on 23 May 2019
Novartis CEO plans gene therapy price 'far lower' than $4 million to $5 million range
23 May 2019 - Novartis AG’s top executive said on Wednesday it expects to price its gene therapy for spinal muscular atrophy “far lower” than the $4 million to $5 million figure the Swiss drug maker has said it could be worth.
U.S. regulators are expected to make a decision this month on whether to approve Zolgensma, a one-time therapy seen as a potential long-term solution for the rare disease that is the leading genetic cause of death in infants.
The company has previously said it could price the treatment in a range of $1.5 million to $5 million.
